A Case of Progressive Cholestatic Drug-Induced Liver Injury Due to Terbinafine.

Q3 Medicine Wisconsin Medical Journal Pub Date : 2023-05-01
Dana Ley, Jessica Musto, Adnan Said
{"title":"A Case of Progressive Cholestatic Drug-Induced Liver Injury Due to Terbinafine.","authors":"Dana Ley,&nbsp;Jessica Musto,&nbsp;Adnan Said","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Terbinafine is commonly prescribed for onychomycosis. It rarely leads to severe, prolonged cholestatic drug-induced liver injury. Clinicians should remain vigilant for this complication.</p><p><strong>Case presentation: </strong>A 62-year-old woman was started on terbinafine and developed mixed hepatocellular and cholestatic drug-induced liver injury, confirmed on liver biopsy. The injury became predominantly cholestatic. Unfortunately, she developed coagulopathy with elevated international normalized ratio and progressive drug-induced liver injury with severely elevated alkaline phosphatase and total bilirubin, requiring repeat liver biopsy. Fortunately, she did not develop acute liver failure.</p><p><strong>Discussion: </strong>Prior case reports and series have documented severe cholestatic drug-induced liver injury (although with lesser degree of bilirubin elevation) due to terbinafine, which has very rarely been associated with acute liver failure, need for liver transplantation, and/or death.</p><p><strong>Conclusions: </strong>Non-acetaminophen drug-induced liver injury is idiosyncratic. Complications including acute liver failure and vanishing bile duct syndrome can be slow to develop, so monitoring for them is important over longitudinal follow-up.</p>","PeriodicalId":38747,"journal":{"name":"Wisconsin Medical Journal","volume":"122 2","pages":"138-142"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wisconsin Medical Journal","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Terbinafine is commonly prescribed for onychomycosis. It rarely leads to severe, prolonged cholestatic drug-induced liver injury. Clinicians should remain vigilant for this complication.

Case presentation: A 62-year-old woman was started on terbinafine and developed mixed hepatocellular and cholestatic drug-induced liver injury, confirmed on liver biopsy. The injury became predominantly cholestatic. Unfortunately, she developed coagulopathy with elevated international normalized ratio and progressive drug-induced liver injury with severely elevated alkaline phosphatase and total bilirubin, requiring repeat liver biopsy. Fortunately, she did not develop acute liver failure.

Discussion: Prior case reports and series have documented severe cholestatic drug-induced liver injury (although with lesser degree of bilirubin elevation) due to terbinafine, which has very rarely been associated with acute liver failure, need for liver transplantation, and/or death.

Conclusions: Non-acetaminophen drug-induced liver injury is idiosyncratic. Complications including acute liver failure and vanishing bile duct syndrome can be slow to develop, so monitoring for them is important over longitudinal follow-up.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
特比萘芬致进行性胆汁淤积性药物性肝损伤1例。
简介:特比萘芬通常用于治疗甲真菌病。它很少导致严重的、长期的胆汁淤积性药物性肝损伤。临床医生应该对这种并发症保持警惕。病例介绍:一名62岁妇女开始使用特比萘芬,并发展为肝细胞和胆汁淤积性药物性肝损伤,肝活检证实。损伤主要是胆汁淤积。不幸的是,她出现凝血功能障碍,国际标准化比率升高,进行性药物性肝损伤,碱性磷酸酶和总胆红素严重升高,需要重复肝活检。幸运的是,她没有发展成急性肝功能衰竭。讨论:先前的病例报告和系列文献记录了特比萘芬引起的严重胆汁淤积性药物性肝损伤(尽管胆红素升高程度较低),很少与急性肝功能衰竭、需要肝移植和/或死亡相关。结论:非对乙酰氨基酚药物性肝损伤具有特异性。包括急性肝衰竭和胆管消失综合征在内的并发症可能发展缓慢,因此监测它们比纵向随访更重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Wisconsin Medical Journal
Wisconsin Medical Journal Medicine-Medicine (all)
CiteScore
1.30
自引率
0.00%
发文量
72
期刊介绍: The Wisconsin Medical Society is the largest association of medical doctors in the state with more than 12,000 members dedicated to the best interests of their patients. With that in mind, wisconsinmedicalsociety.org offers patients a unique source for reliable, physician-reviewed medical information. The Wisconsin Medical Society has been a trusted source for health policy leadership since 1841.
期刊最新文献
Age-Appropriate Cancer Screenings Through a Dermatology Len. Stem Cell Science and Regenerative Biology: Tools for Building New Treatments. Amiodarone Pharmacovigilance Through an Intelligent Electronic Health Record Application. Assessment of Uterine Fibroid Knowledge and Educational Interests Among Health Care Professionals. An Unusual Presentation of Blastomycosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1